DE2808203C2 - Arzneimittel, enthaltend p-Chlorphenoxyisobuttersäure-p-chlorphenolester - Google Patents
Arzneimittel, enthaltend p-Chlorphenoxyisobuttersäure-p-chlorphenolesterInfo
- Publication number
- DE2808203C2 DE2808203C2 DE2808203A DE2808203A DE2808203C2 DE 2808203 C2 DE2808203 C2 DE 2808203C2 DE 2808203 A DE2808203 A DE 2808203A DE 2808203 A DE2808203 A DE 2808203A DE 2808203 C2 DE2808203 C2 DE 2808203C2
- Authority
- DE
- Germany
- Prior art keywords
- acid
- ester
- udf54
- udf53
- chlorophenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 p-chlorophenoxyisobutyric acid p-chlorophenol ester Chemical class 0.000 title claims description 11
- 229940126601 medicinal product Drugs 0.000 title 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 239000003315 2-(4-chlorophenoxy)-2-methylpropanoic acid Substances 0.000 description 9
- 229950008441 clofibric acid Drugs 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 206010060755 Type V hyperlipidaemia Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960005049 clofibride Drugs 0.000 description 1
- CXQGFLBVUNUQIA-UHFFFAOYSA-N clofibride Chemical compound CN(C)C(=O)CCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 CXQGFLBVUNUQIA-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001000 lipidemic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003227 pyridoxines Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000007666 subchronic toxicity Effects 0.000 description 1
- 231100000195 subchronic toxicity Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7706689A FR2382892A1 (fr) | 1977-03-08 | 1977-03-08 | Nouveau medicament hypolipidemiant a base d'ester de p-chlorophenol de l'acide p-chlorophenoxyisobutyrique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2808203A1 DE2808203A1 (de) | 1978-09-14 |
| DE2808203C2 true DE2808203C2 (de) | 1987-01-22 |
Family
ID=9187700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2808203A Expired DE2808203C2 (de) | 1977-03-08 | 1978-02-25 | Arzneimittel, enthaltend p-Chlorphenoxyisobuttersäure-p-chlorphenolester |
Country Status (7)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2577924B1 (fr) * | 1985-02-28 | 1987-03-06 | Cortial | Nouvelle methode de fabrication de l'ester de p-chlorophenol de l'acide p-chlorophenoxyisobutyrique |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1348642A (en) * | 1970-10-15 | 1974-03-20 | Howard A N | Hypocholesterolaemic compositions |
-
1977
- 1977-03-08 FR FR7706689A patent/FR2382892A1/fr active Granted
-
1978
- 1978-02-25 DE DE2808203A patent/DE2808203C2/de not_active Expired
- 1978-03-01 CH CH220678A patent/CH628243A5/fr not_active IP Right Cessation
- 1978-03-06 BE BE185696A patent/BE864601A/xx not_active IP Right Cessation
- 1978-03-07 PT PT67753A patent/PT67753A/pt not_active IP Right Cessation
- 1978-03-07 NL NL7802474A patent/NL7802474A/xx not_active Application Discontinuation
- 1978-03-08 US US05/884,497 patent/US4179519A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FR2382892B1 (US08080257-20111220-C00005.png) | 1979-09-07 |
| FR2382892A1 (fr) | 1978-10-06 |
| BE864601A (fr) | 1978-07-03 |
| DE2808203A1 (de) | 1978-09-14 |
| NL7802474A (nl) | 1978-09-12 |
| PT67753A (fr) | 1978-04-01 |
| CH628243A5 (fr) | 1982-02-26 |
| US4179519A (en) | 1979-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3885889T2 (de) | (r)5-pentylamino-5-oxopentanesäure-derivate mit anticholecystokininwirkung. | |
| DE2947624A1 (de) | Beta, gamma -dihydropolyprenylalkohol und diesen enthaltendes blutdrucksenkendes arzneimittel | |
| DE2941288C2 (US08080257-20111220-C00005.png) | ||
| DE1949813B2 (de) | 3-(4-PyrWyl)-4-(2-hydroxyphenyl)-5-alkyl-pyrazole | |
| DE2157272C3 (de) | Verwendung von bis-(p-Chlorphenoxy)acetylharnstoff | |
| EP0100516B1 (de) | 3-Beta-(3'-(Carboxypropionyloxy))-ursa-9(11),12-dien-28-carbonsäure sowie ihre Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2808203C2 (de) | Arzneimittel, enthaltend p-Chlorphenoxyisobuttersäure-p-chlorphenolester | |
| DE1276035B (de) | 4'-Monoester des Cymarols und Verfahren zu deren Herstellung | |
| CH621333A5 (US08080257-20111220-C00005.png) | ||
| DE2337067A1 (de) | Indensaeure-glucuronide | |
| DE2038628C3 (de) | N,N'-Di(carboxyalkyI)-p-phenylendiamine, deren Salze und Diäthylester, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2428200A1 (de) | Essigsaeurederivate, verfahren zu deren herstellung und diese derivate enthaltende arzneimittel | |
| DE3721223A1 (de) | Glycinderivate | |
| DE2748291B2 (de) | Substituierte 13-Benzodioxan-4one und Verfahren zu ihrer Herstellung sowie Verwendung dieser Verbindungen bei der Bekämpfung von Entzündungen | |
| DE69118340T2 (de) | Neue 15-nitro-2-beta, 3 Beta-dihydro und 15-Nitro-2-beta, 3-Beta,6,7-Tetrahydrotabersoninederivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung | |
| DE2618936C3 (de) | N-Acyl-glutamine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
| DE2407016C3 (de) | 2-Alkoxybenzoylaminocarbonsäuren, Verfahren zu deren Herstellung und diese Verbindungen enthaltende antipyretische Mittel | |
| DE1595870C3 (de) | Verfahren zur Herstellung von 3-(o-Methoxyphenoxy)-1,2-propandiolnicotinaten und deren Säureadditionssalzen | |
| DE2406849C3 (de) | Nicotinsäure-trans-3,3,5-trimethylcyclohex-1-yl-ester, Verfahren zu seiner Herstellung und diesen Ester enthaltendes Arzneimittel | |
| DE741154C (de) | Verfahren zur Herstellung von fettloeslichen Derivaten des Vitamins B | |
| DE3718765A1 (de) | Benzoesaeurederivate | |
| DE2141357C3 (de) | Bis-(4-chlorphenoxy)-essigsäureester, Verfahren zu ihrer Herstellung diese Verbindungen enthaltende Arzneimittel | |
| DE1936747C3 (de) | 1,2-Diphenyl-4-n-butyl-4-hydroxymethyl-S.S-dioxopyrazolidin-halbsuccinat | |
| DE1420955C (de) | alpha (o Benzylphenoxy)-beta piperidino propan, dessen Saureadditionssalze sowie Verfahren zur Herstellung dieser Verbm düngen | |
| DE2016057C3 (de) | Eckige Klammer auf (Thenyliden (2)- amino)-oxy] -alkylcarbonsäuren, deren Salze und Alkylester, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |